All In Biotech

Drug Trial Radar · NCT00364923

Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

A Multi-Center, Phase 2, Open-Label Study of (RS)-10-Propargyl-10-Deazaaminopterin (Pralatrexate) With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Last checked: Nov 20, 2026Latest source record: Dec 19, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

115

Actual

Start

Aug 2006

Primary completion

Jan 2009

Study completion Feb 24, 2009

Sponsor

Lead sponsor
Acrotech Biopharma Inc.Industry
Sponsor type
Industry
First posted
Aug 16, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary • Determine the efficacy of pralatrexate with concurrent vitamin B12 and folic acid supplementation when administered to patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) Secondary * Determine the safety of pralatrexate with concurrent vitamin B12 and folic acid supplementation when administered to patients with relapsed or refractory PTCL * Determine the pharmacokinetic (PK) profile of pralatrexate when administered with vitamin B12 and folic acid supplementation

Conditions

  • Peripheral T-cell Lymphoma

Interventions

  • Pralatrexate InjectionDrug

    Pralatrexate 30 mg/m2 via IV push over 3-5 minutes for 6 weeks in a 7 week cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response Rate Per Independent Central ReviewTime frame: Response was assessed at 7 weeks (prior to Cycle 2) and then prior to every other even-numbered cycle (every 14 weeks) until disease progression or death for up to 2 years after initial dose

Locations

32 sites in 6 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California

  • University of California at Los Angeles

    Los Angeles, California

  • Yale University School of Medicine

    New Haven, Connecticut

  • Emory University

    Atlanta, Georgia

  • University of Chicago Hospital

    Chicago, Illinois

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • Tulane Cancer Center

    New Orleans, Louisiana

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Washington University School of Medicine

    St Louis, Missouri

  • Nevada Cancer Institute

    Las Vegas, Nevada

  • The Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • New York Presbyterian Hospital

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • University of Rochester Cancer Center

    Rochester, New York

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • UT MD Anderson Cancer Center

    Houston, Texas

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

  • Cliniques Universitaire Saint-Luc

    Brussels, Belgium

  • Cliniques Universitaires UCL

    Yvoir, Belgium

  • British Columbia Cancer Agency

    Vancouver, British Columbia, Canada

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

  • CHU Henri Mondor

    Créteil, France

  • CHU DIJON - Hôpital d'enfant

    Dijon, France

  • CHU Nice - Hôpital de l'Archet 1

    Nice, France

  • CHU Nantes - Hôtel Dieu

    Paris, France

  • CHU Saint Louis

    Paris, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, France

  • CHU Robert Debré

    Reims, France

  • Ospedale Sant'Orsola - Policlinico Sant'Orsola

    Bologna, Italy

  • St. Georges Hospital

    London, United Kingdom

  • The Royal Marsden NHS Foundation Trust

    Sutton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.